Modality
Bispecific Ab
MOA
AHRant
Target
WEE1
Pathway
Complement
Pancreatic Ca
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
Oct 2019
Phase 1Current
NCT06091944
1,782 pts·Pancreatic Ca
2019-10→TBD·Terminated
1,782 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q4
P1
Termina…
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06091944 | Phase 1 | Pancreatic Ca | Terminated | 1782 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 |